



The human-specific duplicated $\alpha 7$ gene inhibits the ancestral $\alpha 7$, negatively regulating nicotinic acetylcholine receptor-mediated transmitter release

Received for publication, October 22, 2020, and in revised form, January 13, 2021. Published, Papers in Press, January 28, 2021, <https://doi.org/10.1016/j.jbc.2021.100341>

Carolina Martín-Sánchez¹, Eva Alés², Santiago Balseiro-Gómez², Gema Atienza¹, Francisco Arnalich³, Anna Bordas¹, José L. Cedillo¹, María Extremera¹, Arturo Chávez-Reyes⁴ , and Carmen Montiel^{1,*} 

From the ¹Department of Pharmacology and Therapeutics, Medical School, Universidad Autónoma de Madrid, Madrid, Spain; ²Department of Medical Physiology and Biophysics, Medical School, Universidad de Sevilla, Sevilla, Spain; ³Internal Medicine Service, University Hospital La Paz-IdiPAZ, Madrid, Spain; ⁴Medical School, Universidad Finis Terrae, Santiago de Chile, Chile

Edited by Paul Fraser

Gene duplication generates new functions and traits, enabling evolution. Human-specific duplicated genes in particular are primary sources of innovation during our evolution although they have very few known functions. Here we examine the brain function of one of these genes (*CHRFAM7A*) and its product (dup $\alpha 7$ subunit). This gene results from a partial duplication of the ancestral *CHRNA7* gene encoding the $\alpha 7$ subunit that forms the homopentameric $\alpha 7$ nicotinic acetylcholine receptor ($\alpha 7$ -nAChR). The functions of $\alpha 7$ -nAChR in the brain are well defined, including the modulation of synaptic transmission and plasticity underlying normal attention, cognition, learning, and memory processes. However, the role of the dup $\alpha 7$ subunit remains unexplored at the neuronal level. Here, we characterize that role by combining immunoblotting, quantitative RT-PCR and FRET techniques with functional assays of $\alpha 7$ -nAChR activity using human neuroblastoma SH-SY5Y cell variants with different dup $\alpha 7$ expression levels. Our findings reveal a physical interaction between dup $\alpha 7$ and $\alpha 7$ subunits in fluorescent protein-tagged dup $\alpha 7/\alpha 7$ transfected cells that negatively affects normal $\alpha 7$ -nAChR activity. Specifically, in both single cells and cell populations, the $[Ca^{2+}]_i$ signal and the exocytotic response induced by selective stimulation of $\alpha 7$ -nAChR were either significantly inhibited by stable dup $\alpha 7$ overexpression or augmented after silencing *dup $\alpha 7$* gene expression with specific siRNAs. These findings identify a new role for the dup $\alpha 7$ subunit as a negative regulator of $\alpha 7$ -nAChR-mediated control of exocytotic neurotransmitter release. If this effect is excessive, it would result in an impaired synaptic transmission that could underlie the neurocognitive and neuropsychiatric disorders associated with $\alpha 7$ -nAChR dysfunction.

The $\alpha 7$ nicotinic acetylcholine receptor ($\alpha 7$ -nAChR) is a ligand-gated ion channel expressed in neurons and non-neuronal cells of the human brain where it mostly forms homopentameric receptors composed of five $\alpha 7$ subunits (1,

2). This nAChR subtype is widely distributed in the central nervous system (CNS), although its expression is particularly prominent in the hippocampus and prefrontal cortex, two key regions involved in neurocognitive function (see Ref. (3) and references therein). The $\alpha 7$ -nAChR presents a rapid desensitization and a high permeability to Ca^{2+} that exceeds that of NMDA receptors, implying that the former receptor can act as a precise modulator of the intracellular Ca^{2+} concentration $[Ca^{2+}]_i$ that triggers multiple responses in neurons (1, 4–7). At the subcellular level, activation of presynaptic $\alpha 7$ -nAChRs on nerve terminals in the hippocampus and other brain regions facilitates the exocytotic release of several neurotransmitters, including GABA, glutamate, dopamine, and noradrenaline, while in a postsynaptic location, these receptors activate multiple signaling cascades that promote neuronal plasticity and cell survival processes (8–24).

Given the determinant role of $\alpha 7$ -nAChRs regulating the CNS synaptic transmission and plasticity that underlie the normal processes of attention, cognition, learning, and memory (See Ref. (25) and references therein), receptor dysfunction due to decreased expression and/or activity has been linked to a wide array of neurocognitive disorders, including Alzheimer's disease, schizophrenia, bipolar disorder, attention deficit hyperactivity, autism, and epilepsy (23, 26–29). Hence, it is a huge challenge to identify endogenous or exogenous mechanisms that could alter $\alpha 7$ -nAChR activity and thereby contribute to managing the abovementioned disorders.

Recently our group identified a possible endogenous candidate that may interfere with $\alpha 7$ -nAChR function, the *CHRFAM7A* chimeric gene, which is evolutionarily a relatively recent gene since it appears in the human genome after its divergence from other higher primates (30). The new hybrid gene results from partial duplication (exons 5–10) of the parent *CHRNA7* gene, coding the $\alpha 7$ subunit that forms the $\alpha 7$ -nAChR, fused to the *FAM7A* genetic element (31, 32). Although *CHRFAM7A* expression has been associated with neurocognitive disorders such as schizophrenia, psychosis, bipolar disorder, autism, and dementia (33–35), the functional role of the chimeric gene was long unidentified until we reported that its product, the dup $\alpha 7$ subunit, acted as a

* For correspondence: Carmen Montiel, carmen.montiel@uam.es.

dupa7 controls $\alpha 7$ -nAChR-mediated neurotransmitter release

dominant negative regulator of $\alpha 7$ -nAChR-induced currents in a pioneering electrophysiological study conducted in *Xenopus* oocytes (36). Our finding was corroborated shortly afterward by others, also in oocytes (37) and, a few years later, by our own group in diverse mammalian cell types. Thus, we reported that dupa7 overexpression inhibits, both *in vitro* and *in vivo*, $\alpha 7$ -nAChR-mediated protumorigenic activity in human cell lines from non-small-cell lung cancer (NSCLC) (38). Furthermore, using GH4C1 rat pituitary cells and RAW264.7 mouse macrophages transfected with epitope- or fluorescent protein-tagged $\alpha 7$ or dupa7 constructs, we identified the mechanism underlying dupa7 interference in $\alpha 7$ -nAChR function. This mechanism consists of the physical interaction between dupa7 and $\alpha 7$ subunits generating heteromeric nAChRs that largely remain mainly trapped in the endoplasmic reticulum (39). Thus, the dupa7 sequestration of $\alpha 7$ subunits reduced membrane expression of functional homomeric $\alpha 7$ -nAChRs, attenuating their recognized anti-inflammatory capacity in lipopolysaccharide-stimulated macrophages (39).

The $\alpha 7$ subunit and its duplicate form are naturally coexpressed in the same human cell types, including neuronal, immune, or tumor cells (see Ref. (40) and references there). Thus, it is to be expected that the dupa7 subunit would behave as an endogenous negative regulator of $\alpha 7$ -nAChR-mediated activity in neurons, just as it does in macrophages or tumor cells (38, 39). This last hypothesis, still unexplored, is the one addressed here using the SH-SY5Y human neuroblastoma cell line to assess: (i) the physical interaction between $\alpha 7$ and dupa7 subunits in fluorescent protein-tagged $\alpha 7$ /dupa7 transfected cells; and (ii) the functional impact of the above interaction in cell variants with different dupa7 expression levels. Immunoblotting, quantitative real-time polymerase chain reaction (RT-PCR), Förster resonance energy transfer (FRET) analysis combined with functional assays of $\alpha 7$ -nAChR-activity, in either single cells or cell populations of the above cell variants, allowed us to establish that the dupa7 subunit negatively regulates $\alpha 7$ -nAChR-mediated control of exocytotic neurotransmitter release in neuronal cell types.

Results

Selection of clones with stable overexpression of dupa7

In order to avoid differences in the expression levels of dupa7 mRNA among different SH-SY5Y cultures transiently transfected with the dupa7.pcDNA3.1/Myc-His construct, we stably transfected the cells with this construct, or with its corresponding empty vector pcDNA3.1/Myc-His, as described in the corresponding Methods section. A total of seven positive clones resistant to G418 obtained by lipofection (L1 and L2) or nucleofection (N1–N5) of dupa7-Myc were initially selected. In all of them, the dupa7 or $\alpha 7$ mRNA levels were analyzed by qPCR in order to select those clones that, together with the clear overexpression of dupa7, presented endogenous $\alpha 7$ mRNA levels similar to those found in nontransfected cells (Control). We found two clones (L1 and N1) that fit the above requirements (Fig. 1, panels A and B). Since dupa7 mRNA

overexpression is much more pronounced in the N1 than in the L1 clones, we proceeded to determine if this difference was maintained at the protein level. Immunoblot data using the anti-Myc antibody to detect the foreign dupa7-Myc protein overexpressed in L1 and N1 clones show that there were no significant differences in protein expression levels (Fig. 1C), so both clones were assayed in parallel throughout our study.

Physical interaction of $\alpha 7$ and dupa7 subunits in SH-SY5Y cells

Using FRET confocal imaging analysis in SH-SY5Y cells cotransfected with two pairs of $\alpha 7$ and dupa7 constructs ($\alpha 7$ -GFP:dupa7-Cherry or dupa7-GFP: $\alpha 7$ -Cherry), we evaluated whether dupa7 could physically interact with $\alpha 7$ subunits, thus modulating the $\alpha 7$ -nAChR-mediated control of neurotransmission. The results (Fig. 1D) provide evidence that both nAChR subunits were in sufficient proximity to interact with each other as part of a heteropentameric nAChR. Thus, the left panel of the figure shows representative confocal images acquired before (pre) and after (post) acceptor [$\alpha 7$ -Cherry] photobleaching at 561 nm in the framed area; the increase in emission at 488 nm of the donor [dupa7-GFP (post)] in the cell analyzed after coexpression of the dupa7-GFP: $\alpha 7$ -Cherry pair is worth noting. The right panel of the figure represents the scatter plots of individual data points corresponding to the FRET efficiency values, expressed as a percentage of the maximum efficiency, obtained in the region selected for acceptor photobleaching in cells transfected with the two pairs of constructs assayed in this study at a 1:1 ratio. The error bars represent mean \pm standard deviation (SD). The significantly higher FRET efficiency values when dupa7 was the donor of the pair are also worth noting. Consequently, the subsequent experiments were designed to evaluate the functional consequences of this dupa7/ $\alpha 7$ interaction, in both cell populations and single cells.

Overexpression of dupa7 reduces the $[Ca^{2+}]_i$ signal evoked by $\alpha 7$ -nAChRs in populations of SH-SY5Y cells

One of the most distinctive functions of $\alpha 7$ -nAChR in neurons is to promote the exocytotic release of several neurotransmitters as the result of the $[Ca^{2+}]_i$ rise induced by receptor stimulation. Therefore, the next experiments aimed to evaluate whether overexpression of dupa7 in SH-SY5Y cells interfered with the $[Ca^{2+}]_i$ response induced by 1-s pulses of increasing concentrations of PNU 282987 (1 nM up to 10 μ M) applied to cell populations. To amplify the responses induced by the selective $\alpha 7$ -nAChR agonist and thus facilitate the subsequent analysis of their possible modulation by dupa7, a fixed concentration of the positive allosteric modulator (PAM) of the $\alpha 7$ -nAChR (PNU 120596; 0.5 μ M) was added to the cell medium from 10 min before and during the $\alpha 7$ -nAChR agonist pulse. Figure 2A shows the concentration–response curves to the agonist in nontransfected cells (Control), in both the absence and presence of the PAM; it can be observed that the last agent greatly enhanced the agonist-induced response at all tested concentrations. Figure 2B shows the original fluorescence traces induced by different concentrations of PNU




Figure 1. Expression levels of dupa7 and endogenous $\alpha 7$ subunits in control SH-SY5Y cells or in cells with stable dupa7-myc overexpression (Clones). A and B, normalized expression of the mRNAs of both nicotinic subunits determined by qPCR in control cells (value = 1) and in the clones obtained after lipofection (L1 and L2) or nucleofection (N1–N5). The *solid circles* overlaid on the bar graphs represent individual data points obtained in independent cultures for each condition. The error bars show mean \pm SD. $**p < 0.01$ and $***p < 0.001$ after comparison with the control. The two clones (L1 and N1) selected for the subsequent functional study are indicated by the *black arrow*. C, expression level of the foreign dupa7-myc protein, determined by immunoblot with the anti-myc antibody, in control cells or in the selected clones. At the *top*, a typical immunoblot; at the *bottom*, the protein expression values normalized with respect to β -actin expression. The error bars show mean \pm SD from three independent cultures and *solid circles* the individual values for each condition. $***p < 0.001$ compared with control. D, physical interaction between $\alpha 7$ and dupa7 subunits in SH-SY5Y cells evaluated by FRET efficiency analysis. Cells were transfected with the construct pairs $\alpha 7$ -GFP:dupa7-Cherry or dupa7-GFP: $\alpha 7$ -Cherry, at a ratio of 1:1. On the *left*, representative confocal images of FRET analysis performed in the selected area of a cell cotransfected with dupa7-GFP: $\alpha 7$ -Cherry, where the fluorescence emitted by dupa7-GFP in the framed area is shown before (pre) and after (post) $\alpha 7$ -Cherry photobleaching; scale bar 10 μm . On the *right*, scatter plots (mean \pm SD) representing individual data points of FRET efficiency values (expressed as a percentage) determined in the number of cells analyzed (in parentheses) from three independent cultures. $**p < 0.01$ after comparing the indicated values.

dupa7 controls $\alpha 7$ -nAChR-mediated neurotransmitter release




Figure 2. Effect of *dupa7* overexpression on the $\alpha 7$ -nAChR-mediated $[Ca^{2+}]_i$ signal in populations of SH-SY5Y cells. A, $[Ca^{2+}]_i$ signal induced by increasing concentrations of the selective $\alpha 7$ -nAChR agonist, PNU 282987 (1 nM–10 μ M), in the absence or presence of PNU 120596 (0.5 μ M), a positive allosteric modulator (PAM) of the receptor. Peak fluorescence values induced by the agonist in both experimental conditions, obtained in triplicate, were expressed as a percentage of $F_{max} - F_{min}$ (mean \pm S.E.M.) and correspond to four independent cell cultures. $**p < 0.01$ and $***p < 0.001$ after comparing the same concentration of the agonist in both curves. B, original traces of fluorescence intensity induced by increasing concentrations of PNU 282987 (+PAM) in control cells (black traces; left panel) or in cells expanded from the N1 clone (red traces; right panel). The signal was monitored for 35 s and the PNU 282987 (agonist) was added after measuring basal fluorescence for 5 s, as is indicated by the arrow. C and D, pooled results of the normalized $[Ca^{2+}]_i$ responses ($\Delta[Ca^{2+}]_i$) evoked by increasing concentrations of PNU 282987 (+PAM) in the four cell variants tested [control cells, clones L1 and N1 or transfected with empty vector]; finally, a depolarizing stimulus of high K⁺ (70 mM; 1 s) was applied at the end of the experiment. The $\Delta[Ca^{2+}]_i$ signals were normalized as a percentage of the maximum response induced by PNU 282987 (3 μ M; 100%) in control cells (panel C) or in the corresponding cell variant (panel D). Values are mean \pm S.E.M. from the number of independent cultures indicated in parentheses for each cell variant in panel C. Table inserted (at the right of panel D) shows the EC₅₀ and Slope values obtained from the concentration–response curves of PNU 282987 in the four cell variants tested.

dupa7 controls $\alpha 7$ -nAChR-mediated neurotransmitter release

282987 (+PAM) in control cells (black traces; left panel) or in cells expanded from the N1 clone (red traces; right panel). Figure 2, C and D show pooled results from independent cultures ($n = 4-12$) of normalized $[Ca^{2+}]_i$ responses ($\Delta[Ca^{2+}]_i$) evoked by increasing concentrations of PNU 282987 in the four cell variants tested [control cells, and cells overexpressing

dupa7 (clones L1 and N1), or empty vector]. The $\Delta[Ca^{2+}]_i$ signals were normalized as a percentage of the maximum response induced by PNU 282987 (3 μM ; 100%) in control cells (Fig. 2C) or in the corresponding cell variant (Fig. 2D). The analysis of variance (ANOVA) applied to data in Figure 2C showed that while the $\Delta[Ca^{2+}]_i$ signal induced by




Figure 3. Analysis of various kinetic parameters related to the $[Ca^{2+}]_i$ signal generated by PNU 282987 or high K^+ in single control or dupa7-overexpressing SH-SY5Y cells. A, original traces of fluorescence signal (ΔF_{Ratio}) induced by two successive pulses [1 μM PNU 282987 (+PAM, 1 μM) and 100 mM K^+] applied 1 min apart to a Control cell or to a cell from Clone L1. B, time-course of the normalized $[Ca^{2+}]_i$ signal generated by the $\alpha 7$ -nAChR agonist (+PAM) in individual cells from the three cell variants assayed (control and N1 and L1 clones). Each value represents mean \pm S.E.M. of three cells for each variant. C, scatter plots of individual data points relative to different kinetic parameters obtained from the analysis of the $[Ca^{2+}]_i$ signal evoked by PNU 282987 (+PAM) or high K^+ in single cells corresponding to the three cell variants assayed. In parentheses, the number of cells from each variant. The error bars show mean \pm SD. * $p < 0.05$ and *** $p < 0.001$ after comparing the indicated values.

dupa7 controls $\alpha 7$ -nAChR-mediated neurotransmitter release

PNU 282987 in cells overexpressing the empty vector was indistinguishable from that found in control cells, the overexpression of dupa7 significantly reduced the $\alpha 7$ -nAChR-mediated signal, particularly at the highest agonist testing concentrations (from 30 nM to 10 μ M), but not the signal generated by a depolarizing stimulus of high K^+ (70 mM, 1 s). The table inserted in Figure 2D shows the EC_{50} and slope values obtained from the concentration–response curves of PNU 282987 in the four cell variants tested; the application of the above statistical analysis to both parameters did not show significant differences between the $\Delta[Ca^{2+}]_i$ signals generated in the four variants.

Inhibition of the $\alpha 7$ -nAChR-mediated $[Ca^{2+}]_i$ signal in single SH-SY5Y cells by dupa7 overexpression

To gain further insights into dupa7 negative regulation of the $\alpha 7$ -nAChR-induced $[Ca^{2+}]_i$ rise, we evaluated this regulation at the single cell level by fluorescence microscopy. The SH-SY5Y cells tested in these experiments belong to the next three cell variants: control, L1 clone, and N1 clone. Individual cells were stimulated with a 1-min pulse of PNU 282987 (1 μ M) in the presence of PAM (1 μ M) added to the perfusion medium 20 min before and during the application of the stimulus. After a washout period, the cells were exposed to a final high K^+ pulse (100 mM, 30 s) to exclude from subsequent analyses those cells that had not responded to the depolarizing stimulus. Figure 3A shows original traces of the fluorescence increase (ΔF) induced by the above two pulses applied successively in two Fura 2-loaded cells representative of the Control (upper panel) and the L1 clone (lower panel) groups. Note that overexpression of dupa7 markedly reduces the $\alpha 7$ -nAChR-mediated signal but not that induced by the depolarizing stimulus. In fact, the high K^+ -evoked response is higher in the dupa7 overexpressing cell than in the control cell, probably because the $[Ca^{2+}]_i$ signal induced by PNU 282987 in the latter cell had not yet returned to the basal level when the depolarizing stimulus was applied. Figure 3B shows pooled time-course results of the $[Ca^{2+}]_i$ signal evoked by PNU 282987 in 3 to 4 individual cells belonging to each tested cell variant; the signals recorded in the clones were normalized with respect to the signal obtained in control cells. Blockade of the $\alpha 7$ -nAChR-induced signal was clearly seen in L1 and N1 clones with respect to control cells, but there were no significant differences in the blocked signal between the two types of clones. Figure 3C shows scatter plots of individual data points and statistical analyses of different kinetic parameters relative to the $[Ca^{2+}]_i$ signal induced by PNU 282987 or high K^+ in single cells from the three variants (control, clone L1, and clone N1) from independent cultures. The error bars represent mean \pm SD of the values obtained in the number of cells appearing in parentheses. The overexpression of dupa7 significantly reduced the “Peak Amplitude” and the “Area Under the Curve” of the $[Ca^{2+}]_i$ signal induced by $\alpha 7$ -nAChR but not the signal evoked by the depolarizing stimulus. None of the other analyzed kinetic parameters, independently of

the stimulus, was significantly affected by dupa7 overexpression.

Overexpression of dupa7 reduces the $\alpha 7$ -nAChR-mediated exocytotic response in single SH-SY5Y cells

The $[Ca^{2+}]_i$ rise induced by $\alpha 7$ -nAChRs in neurons activates the SNARE protein complex and the consequent discharge of the vesicular content (neurotransmitter) into the synaptic space by an exocytotic mechanism. Thus, it is likely that the $\alpha 7$ -nAChR-mediated exocytotic response in SH-SY5Y cells is affected by dupa7 overexpression, as is the $[Ca^{2+}]_i$ signal induced by the same receptor subtype. The following experiments were aimed at evaluating this hypothesis at the single cell level. For this, synaptic vesicles of SH-SY5Y cells belonging to the three cell variants tested in this study (control, clone L1, and clone N1) were loaded with the fluorescent FM1-43 dye as described in the corresponding Methods section. Subsequently, the exocytosis of the labeled vesicles was promoted by two successive 1-min pulses of 1 μ M PNU 282987 (+PAM, 1 μ M) and high K^+ (100 mM), separated by a washing period. Figure 4A shows two original destaining traces (loss of the fluorescent signal) indicative of the extent of the exocytotic response induced by the two stimuli in a Control cell and in a cell overexpressing dupa7 (Clone L1). The upper diagram of both registers illustrates the two key steps of what happened with the labeled vesicles in each cell type in response to the two stimuli: 1) PNU 282987 induced vesicular exocytosis (drop in the fluorescent signal) in the Control cell but not in the one with dupa7 overexpression; and 2), in contrast, high K^+ was not able to promote exocytosis of the labeled vesicles in the Control cell (due to its depletion), whereas it did in the L1 cell. Figure 4B shows the timecourse for fluorescence decay in response to PNU 282987 in several cells from each cell variant: Control (n = 3), L1 (n = 3), and N1 (n = 4). Data are expressed as a percentage of the maximum fluorescence (F_0 , considered as 100%) recorded before the application of the stimulus and they represent mean \pm S.E.M. of the values obtained in each cell variant. Figure 4C shows the scatter plots of individual data points reflecting the extent of exocytosis induced by PNU 282987 in single cells from the above cell variants. The values correspond to the maximum drop of fluorescence, expressed as a percentage of F_0 , induced by the nicotinic agonist once the timecourse of the fluorescence decay had stabilized. The error bars represent mean \pm SD of the number of cells indicated in parentheses. The statistical analysis of the above results indicates that dupa7 overexpression significantly reduced the exocytotic response induced by $\alpha 7$ -nAChR in single SH-SY5Y cells, as was expected to occur based on the dupa7 effects on the $[Ca^{2+}]_i$ signal triggered by this receptor subtype in these cells (Figs. 2 and 3).

Silencing dupa7 gene expression with siRNAs positively modulates $\alpha 7$ -nAChR-induced DA release in populations of SH-SY5Y cells

Once it was verified that overexpression of foreign dupa7 subunits negatively regulates $\alpha 7$ -nAChR-mediated exocytotic




Figure 4. Effect of *dupa7* overexpression on the exocytotic responses elicited by PNU 282987 and high K^+ in single control or *dupa7* overexpressing SH-SY5Y cells. Synaptic vesicles were loaded with the fluorescent FM1-43 membrane dye as described in the Method section. The cells were then thoroughly washed and subsequently subjected to two successive stimulations with 1 μ M PNU 282987 (+PAM, 1 μ M) and 100 mM K^+ to induce fusion of labeled vesicles with the plasma membrane and subsequent exocytotic release of FM1-43, which is deduced by the loss of the fluorescent signal of the probe (destaining) in the aqueous solution. **A**, original traces of the fluorescent signal in response to both stimuli applied to a Control cell (*left*) or to a cell overexpressing *dupa7* (Clone L1; *right*). In the *upper part*, diagram representing the FM1-43 dye used to evaluate the exocytotic responses to different stimuli in individual cells. **B**, timecourse of the fluorescent signal decay (destaining) reflecting the PNU 282987-induced exocytotic response in control cells or in cells from L1 and N1 clones; values represent mean \pm S.E.M. from several cells ($n = 3-4$) for each cell variant. F_0 corresponds to the maximum fluorescence (100%) before the addition of the stimulus (*black arrow*). **C**, scatter plots of individual data points reflecting the percentage of the exocytotic response induced by PNU 282987 in single cells from the three cell variants; error bars show mean \pm SD of the number of cells analyzed for each variant (in parentheses). * $p < 0.05$ and *** $p < 0.001$ compared with control cells.

response in single SH-SY5Y cells (Fig. 4), we sought to explore whether endogenous *dupa7* subunits expressed in this human neuronal cell model actually have a functional role in the control of $\alpha 7$ -nAChR-mediated neurotransmission. To explore this possibility, we silenced *dupa7* gene expression with three specific siRNAs, using a commercial siRNA (control siRNA) as negative control. The silencing effectiveness of each siRNA was double-checked by RT-PCR and immunoblot. The results of both analyses revealed that while siRNA-2 was ineffective in silencing gene expression, siRNA-1 and siRNA-3 significantly reduced it, both at the mRNA (Fig. 5A) and at the protein (Fig. 5, panels B and C) levels. Figure 5 (panels A–C) also confirms the specificity of the last two siRNAs in silencing *dupa7* gene expression without affecting the expression of the parent $\alpha 7$ gene, despite the high homology between the nucleotide sequences of both genes. The original immunoblot (Fig. 5C) shows that the sc-5544 antibody recognized two bands of different sizes in the same membrane that correspond to the $\alpha 7$ (≈ 57 kDa) and *dupa7* (≈ 41 kDa) subunits. Note that the heavy expression of $\alpha 7$ makes it difficult to see *dupa7*

expression in the same membrane. To overcome this drawback and better visualize the band corresponding to the duplicated subunit, the membrane of the immunoblot was cut above the 43 kDa molecular weight marker before being incubated with the antibody (Fig. 5B, bottom). Since siRNA-1 was slightly more efficient than siRNA-3 in silencing *dupa7* gene expression, the former was chosen to evaluate the functional role of endogenous *dupa7* in regulating $\alpha 7$ -nAChR-mediated exocytotic dopamine (DA) release in populations of SH-SY5Y cells. To carry out these experiments, neurotransmitter release in response to 1 μ M PNU 282987 (+PAM, 0.5 μ M) or high K^+ (100 mM) was determined by ELISA in the following three cell variants: 1) nontransfected; 2) with stable overexpression of foreign *dupa7* protein (clone N1); or 3) with silenced endogenous expression of *dupa7* (siRNA-1). Figure 5D shows the bar graph and the error bars (mean \pm SD) of the net DA release induced by cell incubation (3.5 min) with one or the other stimulus for each experimental condition assayed in three to four independent cell cultures. The solid circles overlaid with the bar graphs represent individual data

dupa7 controls $\alpha 7$ -nAChR-mediated neurotransmitter release




Figure 5. Silencing effectiveness of different siRNAs on *dupa7* gene expression and its functional consequence on $\alpha 7$ -nAChR-mediated neurotransmitter release in populations of SH-SY5Y cells. The efficacy of three different siRNAs designed for selectively silencing *CHRFAM7A* gene expression was double-checked by qPCR and immunoblot. **A**, bar graph showing mean \pm SD of the normalized expression of *dupa7* and $\alpha 7$ mRNAs in cells transfected with the tested siRNAs (1, 2 or 3); cells transfected with a commercial siRNA (control siRNA) and nontransfected cells were used as negative and positive controls, respectively. **B**, bar graph representing mean \pm SD of the *dupa7*/ β -actin or $\alpha 7$ / β -actin protein ratio determined in the same population of cells assayed above; at the *bottom*, one original blot of a membrane cut above the 43 kDa molecular marker and incubated with the sc-5544 antibody to exclusively view the endogenous *dupa7* subunit (≈ 41 kDa). *Solid circles* overlaid on the bar graphs in panels **A** and **B** represent individual data points obtained in independent cultures for each condition. * $p < 0.05$, ** $p < 0.01$ and *** $p < 0.001$ compared with non-transfected cells. **C**, original blot of a single membrane incubated with the sc-5544 antibody that recognizes two bands whose sizes correspond to the $\alpha 7$ (≈ 57 kDa) and *dupa7* proteins. Only siRNA-1 and siRNA-3 showed selectivity and effectiveness in silencing *dupa7* mRNA and protein expression, leaving the parent *CHRNA7* gene expression unchanged. **D**, exocytotic dopamine (DA) release induced by 1 μ M PNU 282987 (+PAM, 0.5 μ M) or high K^+ (100 mM) in populations belonging to three cell types: nontransfected, with stable *dupa7* overexpression (clone N1), and with endogenous *dupa7* silencing with siRNA-1. Net DA release, determined by ELISA, was normalized to the cell protein content. *Solid circles* overlaid on the bar graph represent individual data points obtained in 3 to 4 independent cultures for each condition. The error bars show mean \pm SD. * $p < 0.05$ and *** $p < 0.001$ after comparing the indicated values.

points obtained for each condition. Compared with non-transfected cells, the silencing of dupa7 expression significantly increased (by more than twice) the $\alpha 7$ -nAChR-induced secretory response, while overexpression of the duplicated subunit significantly reduced that response, as we had previously observed with the exocytotic process in single cells (Fig. 4). In contrast, the secretory response induced by the depolarizing stimulus remained unchanged whatever the level of dupa7 expression in the cells (Fig. 5D).

Discussion

The $\alpha 7$ -nAChR is highly expressed in the human brain, where it exercises essential and well-defined functions that include, among many others, the control of cellular Ca^{2+} signaling and synaptic transmission. The present study characterizes, for the first time in a neuronal cell model, the negative regulation of these important receptor-mediated functions by the human-specific duplicated $\alpha 7$ form, dupa7. Our data, in single cells and in cell populations, reveal that both the $[\text{Ca}^{2+}]_i$ signal and the exocytotic response generated by selective stimulation of $\alpha 7$ -nAChRs were either significantly inhibited by stable overexpression of dupa7 or augmented after silencing dupa7 gene expression with specific siRNAs.

Listed below are the reasons that respectively motivated the selection of SH-SY5Y cells and the dupa7.pcDNA3.1/Myc-His construct as the neuronal model and tool to identify positive clones with stable dupa7 overexpression in our study: 1) the cell line endogenously expresses functional $\alpha 7$ -nAChRs whose activation promotes an exocytotic dopamine release that mimics what occurs in the cortical, hippocampal, or striatal neurons (17, 20, 41, 42); 2) as human cells, SH-SY5Y naturally express dupa7 subunits; 3) the construct contains the -Myc-epitope that allows it to pick up positive clones overexpressing dupa7 since, otherwise, the high homology in the peptide sequences between the dupa7 and $\alpha 7$ subunits causes commercially available antibodies to cross-react with both proteins preventing immunocytochemical identification of dupa7 overexpressing clones; 4) the small size of the -Myc-epitope (10 aa) used to recognize the dupa7 subunit would not interfere with heteromeric $\alpha 7$ /dupa7-nAChR activity, differently from the bulky Cherry or GFP fluorescent proteins.

Our first data reveal that transfection efficiency (number of positive clones) of the above construct in SH-SY5Y cells is higher after nucleofection than lipofection (data not shown), as also reported in other mammalian cell lines (43–45). Moreover, the dupa7 mRNA expression level was significantly higher in selected positive clones obtained by construct nucleofection (clones N1–N5) than in those obtained by lipofection (clones L1 and L2) (Fig. 1, A and B; left panels). This last finding could be due to plasmid distribution within the cell differing in accordance with the transfection method employed. Thus, the concentration of the plasmid in the cytoplasm of lipofected cells would be higher than in nucleofected ones due to a lower integration of the episome into the cellular chromosomal DNA (46).

In contrast to what would be expected from the above mRNA data, no significant differences were found in the

dupa7-Myc protein expression levels between the two clone types, L1 and N1, obtained by lipofection or nucleofection (Fig. 1C). Although a general dogma in molecular biology is the existence of a direct correlation between mRNA and protein levels, this correlation is not found for certain messenger/protein pairs (47, 48). This lack of correlation could be due to the fact that translation of mRNA into protein is conditioned by multiple factors, such as the density of the ribosomes in the cell, the protein synthesis rates, or the existence of mRNA levels that exceed the capacity of cell translation because part of the mRNA occupies the polysomes (“ribosomal occupation”), thereby preventing the efficient translation of the remaining mRNA (49–52).

FRET efficiency values (Fig. 1D) in the cells transfected with the two pairs of fluorescent protein-tagged $\alpha 7$ and dupa7 constructs used here ($\alpha 7$ -GFP:dupa7-Cherry and dupa7-GFP: $\alpha 7$ -Cherry) reveal that both nicotinic subunits are able to interact physically with each other, probably forming heteropentameric nAChRs, as we had previously reported in other mammalian cell types, such as GH4C1 or RAW264.7 cells (39). However, it should be noted that FRET efficiency values differ substantially among the three mammalian cell types so far assayed in our laboratory, with RAW264.7 showing the highest values (39) and SH-SY5Y the lowest (present study). This finding is probably a consequence of a native expression of dupa7 subunits in SH-SY5Y cells but not in RAW264.7 or GH4C1 cells. Therefore, unlike the last two cell types, dupa7 subunits naturally expressed in SH-SY5Y cells could interfere with the assembly process of foreign fluorescent protein-tagged dupa7 and $\alpha 7$ subunits expressed in the cell, the latter being the subunits actually detected in the FRET analysis. Thus, the higher the endogenous expression of dupa7, the lower the FRET value reached in the cell. It is also interesting to note that when SH-SY5Y cells were transfected with the two pairs of constructs used in our study, the FRET efficiency values were significantly higher when the energy donor molecule (GFP) of the couple was dupa7 (Fig. 1D, scatter plots). This last finding agrees with our own previous data in RAW264.7 cells (39) as well as with data from another group in mouse neuroblastoma Neuro2A cells (53). The authors of the latter study justified their results by the low translation rate of dupa7 mRNA into its corresponding protein compared with that of $\alpha 7$ mRNA. Thus, dupa7-GFP subunits (acting as a donor) were more likely to lie adjacent to $\alpha 7$ -Cherry subunits in the heteromeric nAChR than the alternative, that is, dupa7-Cherry subunits would be found in the vicinity of $\alpha 7$ -GFP subunits forming the heteromeric nAChR.

Based on the above data as well as on previous findings by our group and others in *Xenopus* oocytes and in several mammalian cell lines, such as neuroendocrine GH4C1, immune RAW264.7, BOSC-23 kidney, or human NSCLC cells (36, 37, 39, 54, 55), we propose that dupa7 subunits could be colocalized with full-length $\alpha 7$ subunits in SH-SY5Y cells forming heteromeric dupa7/ $\alpha 7$ -nAChRs to the detriment of fully functional homomeric $\alpha 7$ -nAChR expression. If our proposal is true, then overexpression of dupa7 in SH-SY5Y

dupa7 controls $\alpha 7$ -nAChR-mediated neurotransmitter release

cells would result in a decreased cellular responsiveness to $\alpha 7$ -nAChR stimulation. The functional data produced by selective stimulation of $\alpha 7$ -nAChRs in four variants of SH-SY5Y cells (control, empty-vector transfected cells, or clones L1 and N1) corroborates the above hypothesis and will be discussed below.

Clones L1 and N1 are the ones selected here for functional studies as they show a similar extent of *dupa7* protein overexpression (Fig. 1C) without modification of the endogenous $\alpha 7$ mRNA levels of control cells (Fig. 1, A and B; right panels). The results obtained in cell populations from both clones reveal that *dupa7* overexpression significantly reduces the $[Ca^{2+}]_i$ signal generated by selective activation of $\alpha 7$ -nAChR with the agonist PNU 282987 compared with signals in control or empty-vector transfected cells (56) (Fig. 2, B and C). As expected from previous studies (57, 58), the addition of the PAM-type II agent (PNU 120596) amplified the agonist-induced signal, as is clearly verifiable in control cells (Fig. 2A). Interestingly, the above *dupa7* effect in cell populations was reproduced at the single-cell level, as evidenced by the significant reduction of the “Peak Amplitude” and “Area Under the Curve” of the $[Ca^{2+}]_i$ signal generated by selective stimulation of $\alpha 7$ -nAChRs in individual cells from clones L1 or N1 compared with control cells (Fig. 3). The inability of PNU 282987 to induce a vigorous $[Ca^{2+}]_i$ signal in the two selected L1 and N1 clones, when compared with that achieved in control or empty vector-transfected cells, was not due to: 1) a deterioration in cell responsiveness since the four cell variants used in our study produce a similar $[Ca^{2+}]_i$ rise in response to a depolarizing stimulus, such as high K^+ , both in cell populations and in individual cells (Figs. 2C and 3); or 2) a decrease in the affinity of PNU 282987 for the expressed nAChR given the similarity of the EC_{50} values for the agonist found in the four evaluated cell variants (Fig. 2D, inserted table). Therefore, the above loss of effectiveness of PNU 282987 in clones L1 and N1 would be better explained on the basis of a reduction in the number of functional $\alpha 7$ -nAChRs expressed on the cell surface in these latter cell variants as a result of *dupa7* overexpression. Our interpretation was supported by previous studies in oocytes, RAW264.7, or PC12 cells that show that *dupa7* overexpression significantly reduces the number of α -Bgtx binding sites on the cell membrane (36, 39, 55).

It is well known that the $[Ca^{2+}]_i$ rise induced by activation of $\alpha 7$ -nAChRs in SH-SY5Y cells leads to exocytotic neurotransmitter (DA) release. Therefore, it is foreseeable that *dupa7* overexpression in these cells would also cause a significant reduction in release of that transmitter. Our results in single cells from L1 or N1 clones indicate that this is the case (Fig. 4). Even more interesting, if possible, is the finding that *dupa7* subunits naturally expressed by SH-SY5Y cells are capable of controlling the extent of exocytotic activity mediated by native $\alpha 7$ -nAChRs, as deduced from the potentiation of the receptor-induced DA release in cell populations (Fig. 5D) after *dupa7* gene silencing with specific siRNAs (Fig. 5, A–C). This latter finding suggests the presence of a “ $\alpha 7$ -nAChR tone” in CNS neurons that, maintained by naturally expressed *dupa7* subunits, would regulate physiological synaptic transmission. This balanced crosstalk between *dupa7* and $\alpha 7$ -nAChRs could be

lost when changes in the expression of the duplicate subunit secondary to certain pathological processes occur. It is also interesting to note that *dupa7* gene silencing with siRNA-1 enhances the $\alpha 7$ -nAChR-mediated transmitter release only, but not that induced by cell depolarization with high K^+ , supporting the idea that the duplicated subunit acts by selectively interfering with ancestral receptor activity but not with any other kind of cell stimulus.

In summary, our study reveals that the *dupa7* subunit behaves as a negative endogenous modulator of the exocytotic transmitter release controlled by $\alpha 7$ -nAChRs in a human neuronal cell model, as we have previously demonstrated with other $\alpha 7$ -nAChR-mediated functions in immune or tumoral cells (38, 39). Impaired expression and function of $\alpha 7$ -nAChRs have been implicated in the pathogenesis of many neurological and psychiatric disorders (see Ref. (23) and references therein). In fact, other studies have established an association between the *CHRFAM7A* gene and certain neurocognitive diseases. Therefore, we propose that an upregulated expression of the latter gene, triggered by a yet unknown mechanism, could contribute to some of the above disorders mediated by deficient $\alpha 7$ -nAChR activity in the CNS. This last proposal is strongly supported by the Kunni and colleagues study reporting an altered ratio of *CHRFAM7A/CHRNA7* transcripts (mainly due to overexpression of *dupa7* mRNA) in postmortem dorsolateral prefrontal cortex of subjects with schizophrenia and bipolar disorder compared with control nonpsychiatric group (34).

Experimental procedures

Cell culture and reagents

Human neuroblastoma SH-SY5Y cell line was purchased from American Type Culture Collection ATCC. Cells were maintained in a Dulbecco's Modified Eagle Medium-F12 (DMEM-F12) from GIBCO (ThermoFisher Scientific) supplemented with 10% fetal calf serum, glutamax (1 \times), penicillin G sodium (100 units/ml), and streptomycin sulfate (100 μ g/ml) in a 5% CO_2 humidified incubator at 37 $^{\circ}C$. Primary mouse anti-Myc and goat anti- β -actin monoclonal antibodies were purchased from Roche and Sigma-Aldrich, respectively. Primary rabbit polyclonal anti- $\alpha 7$ /anti-*dupa7* antibody (sc-5544) and secondary (HRP)-conjugated anti-mouse IgG and anti-goat IgG antibodies were obtained from Santa Cruz Biotechnology, while the secondary (HRP)-conjugated anti-rabbit IgG antibody was purchased from Bio-Rad. The siRNAs (1 and 3) were designed by one of the study authors (A. Chávez-Reyes) and synthesized by Ambion (ThermoFisher Scientific), while siRNA-2 and “siRNA negative control” were from Qiagen. PNU 282987 and PNU 120596 were from Abcam and Tocris Bioscience, respectively. Dopamine and geneticin (G418) were from Sigma-Aldrich. Dopamine High Sensitive ELISA kit was from DLD Diagnostika GMBH. The Lipofectamine 2000 and Nucleofection kits were from Invitrogen and Amaxa Biosystems, Lonza, respectively. The acetoxymethyl ester form (AM) of the fluorescent Ca^{2+} indicators Fluo-4 and Fluo-2 and

the FM1-43 membrane probe were from Molecular Probes, Invitrogen.

SH-SY5Y cell transfection and selection of stable overexpressing dupa7-Myc transfectants

The dupa7.pcDNA3.1/Myc-His construct used for transfection was prepared in our laboratory as described elsewhere (39); it contains the full-length human dupa7 cDNA sequence in frame with the Myc-His tag. SH-SY5Y cells were transfected with the above plasmid or the corresponding empty vector (pcDNA3.1/Myc-His) using either the Lipofectamine 2000 or the Nucleofection kits according to the manufacturer's instructions as detailed elsewhere (39). Twenty-four hours after transfection, the cells were trypsinized and replated in culture medium supplemented with the aminoglycoside antibiotic G418 (800 $\mu\text{g/ml}$) used to select antibiotic-resistant stably transfected clones; single positive clones were picked up using cloning cylinders. Messenger and protein expression for dupa7 or $\alpha 7$ in expanded cells derived from each putatively positive clone were respectively analyzed by qPCR or immunoblot as detailed below.

qPCR assay of mRNA expression in SH-SY5Y cells

Techniques for RNA extraction from cells and $\alpha 7$ or dupa7 mRNA expression analysis by qPCR from reverse-transcribed RNA using the SYBR green-based assays (Bio-Rad) and the ABI Prism 7500 Sequence Detector (Applied Biosystems) have been described elsewhere (39, 59, 60). Briefly, total RNA was extracted from SH-SY5Y cells with the RNeasy Mini kit (Qiagen,) and reverse-transcribed into cDNA using Taqman Reverse Transcription Reagents kit (Life Technology, ThermoFisher Inc) according to the manufacturer's instructions. The PCR amplification was performed using the following cycling conditions: 95 °C for 10 min, followed by 40 cycles at 95 °C for 15 s and 60 °C for 60 s. The primers used for PCR amplification of the corresponding transcript were: dupa7, forward 5'-CAATTGCTAATCCAGCATTGTGG-3' and reverse 5'-CCCAGAAGAATTCACCAACACG-3'; and $\alpha 7$, forward 5'-GCTGCAAATGTCTTGGACAGA-3', and reverse 5'-AACAGTCTTCACCCCTGGATAT-3'. Analysis of the melting curves demonstrated that each pair of primers amplified a single product. The relative mRNA level of target transcripts was normalized with respect to two reference genes, beta-2 microglobulin (*B2M*) and ubiquitin C (*UBC*), using the $2^{-\Delta\Delta C_t}$ method and the SDS 2.0.6 software (Sequence Detection System, Applied Biosystems) as described elsewhere (59, 60). Primers used for PCR amplification of reference genes were: *B2M*, forward 5'-TGCCTGCCGTGTGAACCATGT-3' and reverse 5'-TGCGGCATCTTCAAACCTCCTCCATGA-3'; *UBC*, forward 5'-GTTCCGTTCGACCCGGGATT-3', and reverse 5'-TGCATTGTCAAGTGACGATCACAGC-3'. Student's *t*-test was used for statistical analysis of the data.

Western blotting

SH-SY5Y cells were lysed, and the concentration of proteins in the cell lysates was determined with the BCA assay kit

(Pierce BCA Protein Assay kit, Thermo Fisher Inc). Proteins were resolved by denaturing 7% SDS/PAGE gel electrophoresis, transferred to a PVDF membrane (Millipore Corporation), and immunoblotted with the appropriate antibodies as described elsewhere (36, 39, 61). The dilutions and incubation periods of the primary antibodies used to detect foreign and endogenous dupa7 subunits expressed in the cells were the anti-Myc (1:200; 2 h) and the sc5544 (1:500; 2 h), respectively. Although the last antibody recognizes both the dupa7 and $\alpha 7$ subunits, the first protein is perfectly distinguished from the second due to its smaller size (41 kDa *versus* 57 kDa). The secondary (HRP)-conjugated antibodies, anti-mouse IgG (1:5000) or anti-rabbit IgG (1:4000), were incubated at room temperature for 1 h. The resulting bands corresponding to dupa7 expression were detected using ECL Plus reagents (Amersham, GE Healthcare) and quantified by densitometry using the Image J software (National Institutes of Health, USA) and β -actin as the reference protein. Student's *t*-test was used for statistical analysis of these data.

FRET analysis

The GFP- and pmCherry-N1-tagged constructs for both nAChR subunits ($\alpha 7$ -pGFP, $\alpha 7$ -pmCherry-N1, dupa7-pGFP, and dupa7-pmCherry-N1) were prepared in our laboratory by PCR using the dupa7.pSP64T and $\alpha 7$.pSP64T plasmids as templates and the set of primers described elsewhere (39). SH-SY5Y cells grown on glass coverslips treated with poly-L-lysine were nucleofected with the following two pairs of constructs ($\alpha 7$ -GFP:dupa7-Cherry or dupa7-GFP: $\alpha 7$ -Cherry), at a 1:1 ratio. Forty-eight hours after transfection, cells were fixed, rinsed, and mounted using citifluor AF-2. Images of selected regions in each cell were taken to determine FRET efficiency using the acceptor photobleaching technique and the Leica TCS SP5 Spectral confocal microscope as described elsewhere (39). Efficiency was calculated using the equation: FRET efficiency = $1 - (D_{pre}/D_{post})$; where D_{pre} and D_{post} represent the fluorescence emitted by the donor (GFP) before and after photobleaching of the acceptor (Cherry) using the 561 laser. Student's *t*-test was applied for statistical analysis.

Measurement of $[Ca^{2+}]_i$ in SH-SY5Y cell populations using a microplate reader

Cells were plated in transparent bottom 96-well black plates (5×10^4 cells/well) and incubated during 48 h at 37 °C. Afterward, cells were loaded with Fluo-4 AM (4 μM) and pluronic acid (0.02%) in serum-free culture medium for 45 min at 37 °C in the dark. Then cells were washed twice with Krebs-HEPES solution (in mM) [140 NaCl, 5.6 KCl, 1.2 MgCl_2 , 0.4 CaCl_2 , 10 HEPES, 11 D-glucose, pH 7.4] and kept at room temperature for 15 min before beginning the experiment. To induce the $[Ca^{2+}]_i$ rise, the cells were stimulated with increasing concentrations of a selective $\alpha 7$ -nAChR agonist, PNU 282987. Whenever PNU 282987 was used as a stimulus, a PAM of $\alpha 7$ -nAChR (PNU 120596) was added to the stimulation medium to increase the agonist-induced response. To check the responsiveness of the cell in regard to the $[Ca^{2+}]_i$

dupa7 controls $\alpha 7$ -nAChR-mediated neurotransmitter release

signal, the experimental protocol included a final high K^+ depolarizing pulse. Fluorescence measurements were carried out using the microplate reader FLUOstar Optima (BMG Labtech). Wavelengths of excitation/emission were 485/520 nm and changes in fluorescence were measured at 0.5 s intervals. Once the experiment was finished, 50 μ l Triton X-100 (10%) followed by 50 μ l $MnCl_2$ (1 mM) were added to each well to calculate maximum fluorescence (F_{max}) and minimum fluorescence (F_{min}), respectively. The $[Ca^{2+}]_i$ rise (ΔCa^{2+}) induced by increasing concentrations of PNU 282987 or a high K^+ solution was determined in each cell variant type and represents the percentage of the peak fluorescence value (% F_p) elicited by the stimulus according to the following formula: % $F_p = [(F_p - F_0)/F_{max} - F_{min}] \times 100$; where F_0 is the basal fluorescence value obtained before cell stimulation. All experiments, performed in triplicate, were replicated in several independent cultures. The concentration of PNU 282987 (in μ M) eliciting half-maximal ΔCa^{2+} response (EC_{50}) and the slope in the concentration–response curves corresponding to each cell variant were determined by nonlinear regression using the GraphPad Prism 5 software. Student's t -test was applied for statistical analysis.

Measurement of $[Ca^{2+}]_i$ in single SH-SY5Y cells by fluorescence microscopy

Cells seeding on coverslips (15,000 cells/coverslip) were loaded with 4 μ M of Fura 2-AM and 0.02% of pluronic acid for 45 min at 37 °C in the dark. The cells were thoroughly washed, at room temperature, with Krebs-HEPES solution for 5 min before they were placed in a perfusion chamber on the stage of an Axiovert 200 inverted epifluorescence microscope equipped with filters to excite the probe and capture its emission (XF04-2, Omega Optical). The chamber was continuously superfused, at room temperature, with Krebs-HEPES solution, and cells were stimulated with a fixed concentration of the selective $\alpha 7$ -nAChR agonist, PNU 282987 (+PAM). The experimental design included a final high K^+ depolarizing pulse as a guarantee of cellular functionality. Solutions containing PNU 282987 or high K^+ were changed using a multibarreled concentration-clamp device that electrically controlled the valves. Only one experimental protocol was run on each coverslip. Single-cell fluorescence measurements were performed by exciting the Fura-2-loaded cells with alternating 360- and 380 nm filtered light. The emitted fluorescence was filtered through a 520 nm filter and captured with an ORCA-R2 CCD camera (Hamamatsu Photonics). The data were acquired and stored using HCLImage software and exported to Igor Pro (WaveMetrics) to perform analysis. The fluorescence values induced by the different stimuli were calculated after subtracting the basal fluorescence obtained before cell stimulation. The $[Ca^{2+}]_i$ signal was expressed by the ratio of fluorescence at 360 nm and 380 nm. The increase in the fluorescent signal generated by the $\alpha 7$ -nAChR agonist or by the high K^+ solution represented the change in $[Ca^{2+}]_i$ induced in real time by both stimuli. The kinetic parameters analyzed were: Peak Amplitude (F360/F380 ratio at the peak of

fluorescence), Area Under Curve (or integral over the deviation throughout the transient $[Ca^{2+}]_i$ signal), Time to Peak (time between the application of the stimulus and the fluorescence peak), and Decay Time (time constant for the exponential fit to the decay curve during recovery of the basal $[Ca^{2+}]_i$ signal). The Kruskal–Wallis test followed by the Dunn post-hoc test were used for statistical analysis.

Measurement of exocytosis in single SH-SY5Y cells using the FM1-43 dye

Cells seeded on coverslips (15,000 cells/coverslip) were mounted in the perfusion chamber on the stage of an Axiovert 200 inverted microscope equipped with a 63x PlanNeofluar immersion oil objective. Synaptic vesicles were loaded with the fluorescent FM1-43 membrane dye (4 μ M, 4 min) by substitution of the basal Krebs-HEPES solution in the perfusion with a Krebs-HEPES solution containing 100 mM $[K^+]$ (prepared by equimolar replacement of NaCl by KCl). Next, cells were washed for 10 min with the basal solution to remove the excess FM1-43. Cells were subsequently subjected to two successive stimuli of PNU 282987 (+PAM) and high K^+ (100 mM) to induce the exocytosis of the vesicles labeled with the probe, which was deduced by the loss of the recorded fluorescent signal. Exocytosis of the probe in response to the stimulus was determined by successive captures of images taken in regions of interest (ROI), at 0.5 Hz intervals and 200 ms per capture, using a high-resolution ORCA-R2 CCD camera (Hamamatsu Photonics). Data were acquired and stored using the HCLImage software (Hamamatsu Photonics). Net fluorescence in each ROI at a given time was calculated by subtracting the background fluorescence in an adjacent ROI of the same cell at that time. The destaining traces were graphed as the change in fluorescence (ΔF , absolute values) normalized to the fluorescence at the beginning of the experiment (F_0) (considered as 1 or 100, depending on the representation) using the following equation: $\Delta F/F_0 = (F_F - F_0)/F_0$, where F_F is the point at which the destaining curve slope becomes zero (complete discharge of the previously endocytosed probe). Differences between groups were evaluated for statistical significance using the Kruskal–Wallis test followed by the Dunn post-hoc test. Statistical analysis was performed using the GraphPad Prism software.

Silencing endogenous dupa7 gene expression with siRNAs

SH-SY5Y cells were seeded in 6-well plates (625,000 cells/well) and transfected with three different siRNAs designed to knockout *dupa7* gene expression or with a siRNA control using the *TransIT*-TKO siRNA transfection reagent (Mirus Bio) according to the manufacturer's protocol. Since the $\alpha 7$ and *dupa7* transcripts are highly homologous (>99%) from exon 5 to the 3'-UTR region, the target sequences for the three siRNAs used in this study were located in the divergent region (exons D, C, B and A) of the *dupa7* mRNA sequence that has replaced exons 1 to 4 of the parent *CHRNA7* gene (encoding $\alpha 7$ mRNA). Thus, the sequences of siRNA primers and location of the target sequences (in parentheses) in the *dupa7*

mRNA sequence (NM-139320.1) were the following: siRNA-1, sense: 5'-CAACAUAUAGAUUCAAGUTT-3' and reverse: 5'-ACUUGUAAUCUUAUUGUUGCG-3' (junction region between exons D and C); siRNA-2, sense: 5'-CGGUGGAGUCGGUUAUAAATT-3' and reverse: 5'-UUUAUAA CCGACUCCACCGAC-3' (exon D); and siRNA-3, sense: 5'-CCAUUAUUGACAAUCCAAATT-3' and reverse: 5'-UU UGGAUUGUCAUUAUUGGGG-3' (exon C). Data were expressed as means \pm SD using the Kruskal–Wallis test followed by the Dunn post-hoc test for statistical analysis.

Determination of dopamine release by ELISA

DA released exocytotically into the extracellular medium after stimulation of SH-SY5Y cells was determined using an ELISA kit that detects this neurotransmitter with high sensitivity (lower detection limit of 4.53 pg/ml). To amplify the DA released by the stimulus, cells seeded in 6-well plates (500,000 cells/well) were incubated with exogenous DA (20 nM) for 20 min at 37 °C in order to increase the vesicular content of neurotransmitter. After exposure to the stimulus, the cells in each well were lysed to determine the protein concentration using a BCA protein assay kit, while the corresponding supernatant was collected in a tube containing a stabilizing solution that was immediately frozen at -80 °C until the DA concentration was quantified in a microtiter plate reader (FluOstar Optima, BMG) at 450 nm using a standard curve of known concentrations of exogenous DA. The concentration of DA released in response to a specific stimulus in each cell variant assayed was normalized to the cell protein content and expressed in pg/mg of protein. Differences between groups were evaluated for statistical significance using the one-way ANOVA followed by Tukey post-hoc comparison tests.

Data availability

All relevant data are contained within the article.

Author contributions—C. M., E. A., C. M. -S., and F. A. conceived the study and designed the experiments. C. M. -S., E. A., S. B. -G., and G. A. conducted most of the experiments and analyzed the data. A. B., J. L. C., and M. E. performed the cell transfections and PCR assays. A. C. -R. designed the siRNAs. C. M. wrote the paper with contribution from all the authors. All the authors reviewed the results and approved the final version of the article.

Funding and additional information—This work was supported by a Grant from the Ministry of Economy, Industry and Competitiveness, Government of Spain (SAF2017-82689-R) to C. M. and F. A. C. M. -S. was recipient of an FPI fellowship (Ministry of Economy, Industry and Competitiveness). A. B. was recipient of an FPI fellowship (Autonomous University of Madrid). J. L. C. was recipient of an FPU fellowship (Ministry of Education, Culture and Sports, Government of Spain). M. E. and G. A. were hired with funds from the above Grant.

Conflict of interest—The authors declare that they have no conflicts of interest with the contents of this article.

Abbreviations—The abbreviations used are: $\alpha 7$ -nAChR, $\alpha 7$ subtype of the nicotinic acetylcholine receptor; ACh, acetylcholine; $[Ca^{2+}]_i$, intracellular concentration of Ca^{2+} ; CNS, central nervous system; DA, dopamine; dupa7, partial duplicated isoform of the human $\alpha 7$ nicotinic subunit; FRET, Förster resonance energy transfer; NSCLC, non-small-cell lung cancer; PAM, positive allosteric modulator of $\alpha 7$ -nAChR; qPCR, real-time quantitative polymerase chain reaction; SD, standard deviation.

References

1. Albuquerque, E. X., Pereira, E. F., Alkondon, M., and Rogers, S. W. (2009) Mammalian nicotinic acetylcholine receptors: From structure to function. *Physiol. Rev.* **89**, 73–120
2. Fasoli, F., and Gotti, C. (2015) Structure of neuronal nicotinic receptors. *Curr. Top. Behav. Neurosci.* **23**, 1–17
3. Bertrand, D., Lee, C. L., Flood, D., Marger, F., and Donnelly-Roberts, D. (2015) Therapeutic potential of $\alpha 7$ nicotinic acetylcholine receptors. *Pharmacol. Rev.* **67**, 1025–1073
4. Vijayaraghavan, S., Pugh, P. C., Zhang, Z. W., Rathouz, M. M., and Berg, D. K. (1992) Nicotinic receptors that bind alpha-bungarotoxin on neurons raise intracellular free Ca^{2+} . *Neuron* **8**, 353–362
5. Séguéla, P., Wadiche, J., Dineley-Miller, K., Dani, J. A., and Patrick, J. W. (1993) Molecular cloning, functional properties, and distribution of rat brain alpha 7: A nicotinic cation channel highly permeable to calcium. *J. Neurosci.* **13**, 596–604
6. Williams, D. K., Wang, J., and Papke, R. L. (2011) Investigation of the molecular mechanism of the $\alpha 7$ nicotinic acetylcholine receptor positive allosteric modulator PNU-120596 provides evidence for two distinct desensitized states. *Mol. Pharmacol.* **80**, 1013–1032
7. Uteshev, V. V. (2012) $\alpha 7$ nicotinic ACh receptors as a ligand-gated source of Ca^{2+} ions: The search for a Ca^{2+} optimum. *Adv. Exp. Med. Biol.* **740**, 603–638
8. Girod, R., Barazangi, N., McGehee, D., and Role, L. W. (2000) Facilitation of glutamatergic neurotransmission by presynaptic nicotinic acetylcholine receptors. *Neuropharmacology* **39**, 2715–2725
9. Fabian-Fine, R., Skehel, P., Errington, M. L., Davies, H. A., Sher, E., Stewart, M. G., and Fine, A. (2001) Ultrastructural distribution of the alpha7 nicotinic acetylcholine receptor subunit in rat hippocampus. *J. Neurosci.* **21**, 7993–8003
10. Jones, I. W., and Wonnacott, S. (2004) Precise localization of alpha7 nicotinic acetylcholine receptors on glutamatergic axon terminals in the rat ventral tegmental area. *J. Neurosci.* **24**, 11244–11252
11. Rousseau, S. J., Jones, I. W., Pullar, I. A., and Wonnacott, S. (2005) Presynaptic alpha7 and non-alpha7 nicotinic acetylcholine receptors modulate $[^3H]$ D-aspartate release from rat frontal cortex *in vitro*. *Neuropharmacology* **49**, 59–72
12. Zhu, P. J., Stewart, R. R., McIntosh, J. M., and Weight, F. F. (2005) Activation of nicotinic acetylcholine receptors increases the frequency of spontaneous GABAergic IPSCs in rat basolateral amygdala neurons. *J. Neurophysiol.* **94**, 3081–3091
13. Biton, B., Bergis, O. E., Galli, F., Nedelec, A., Lochead, A. W., Jegham, S., Godet, D., Lanneau, C., Santamaria, R., Chesney, F., LÄ©onardon, J., Granger, P., Debono, M. W., Bohme, G. A., Sgard, F., et al. (2007) SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (1) binding and functional profile. *Neuropsychopharmacology* **32**, 1–16
14. Dani, J. A., and Bertrand, D. (2007) Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. *Annu. Rev. Pharmacol. Toxicol.* **47**, 699–729
15. Dickinson, J. A., Kew, J. N. C., and Wonnacott, S. (2008) Presynaptic alpha 7- and beta 2-containing nicotinic acetylcholine receptors modulate excitatory amino acid release from rat prefrontal cortex nerve terminals via distinct cellular mechanisms. *Mol. Pharmacol.* **74**, 348–359
16. Livingstone, P. D., Srinivasan, J., Kew, J. N. C., Dawson, L. A., Gotti, C., Moretti, M., Shoaib, M., and Wonnacott, S. (2009) Alpha7 and non-alpha7 nicotinic acetylcholine receptors modulate dopamine release

dupa7 controls $\alpha 7$ -nAChR-mediated neurotransmitter release

- in vitro* and *in vivo* in the rat prefrontal cortex. *Eur. J. Neurosci.* **29**, 539–550
17. Sydserff, S., Sutton, E. J., Song, D., Quirk, M. C., Maciag, C., Li, C., Jonak, G., Gurley, D., Gordon, J. C., Christian, E. P., Doherty, J. J., Hudzik, T., Johnson, E., Mrzljak, L., Piser, T., *et al.* (2009) Selective $\alpha 7$ nicotinic receptor activation by AZD0328 enhances cortical dopamine release and improves learning and attentional processes. *Biochem. Pharmacol.* **78**, 880–888
 18. Parikh, V., Ji, J., Decker, M. W., and Sarter, M. (2010) Prefrontal beta2 subunit-containing and $\alpha 7$ nicotinic acetylcholine receptors differentially control glutamatergic and cholinergic signaling. *J. Neurosci.* **30**, 3518–3530
 19. Lozada, A. F., Wang, X., Gounko, N. V., Massey, K. A., Duan, J., Liu, Z., and Berg, D. K. (2012) Glutamatergic synapse formation is promoted by $\alpha 7$ -containing nicotinic acetylcholine receptors. *J. Neurosci.* **32**, 7651–7661
 20. Huang, M., Felix, A. R., Kwon, S., Lowe, D., Wallace, T., Santarelli, L., and Meltzer, H. Y. (2014) The $\alpha 7$ nicotinic receptor partial agonist/5-HT₃ antagonist RG3487 enhances cortical and hippocampal dopamine and acetylcholine release. *Psychopharmacology (Berl.)* **231**, 2199–2210
 21. Huang, M., Felix, A. R., Flood, D. G., Bhuvaneshwaran, C., Hilt, D., Koenig, G., and Meltzer, H. Y. (2014) The novel $\alpha 7$ nicotinic acetylcholine receptor agonist EVP-6124 enhances dopamine, acetylcholine, and glutamate efflux in rat cortex and nucleus accumbens. *Psychopharmacology (Berl.)* **231**, 4541–4551
 22. Koranda, J. L., Cone, J. J., McGehee, D. S., Roitman, M. F., Beeler, J. A., and Zhuang, X. (2014) Nicotinic receptors regulate the dynamic range of dopamine release *in vivo*. *J. Neurophysiol.* **111**, 103–111
 23. Sinkus, M. L., Graw, S., Freedman, R., Ross, R. G., Lester, H. A., and Leonard, S. (2015) The human *CHRNA7* and *CHRFAM7A* genes: A review of the genetics, regulation, and function. *Neuropharmacology* **96**, 274–288
 24. Cheng, Q., and Yakel, J. L. (2015) The effect of $\alpha 7$ nicotinic receptor activation on glutamatergic transmission in the hippocampus. *Biochem. Pharmacol.* **97**, 439–444
 25. Kabbani, N., and Nichols, R. A. (2018) Beyond the channel: Metabotropic signaling by nicotinic receptors. *Trends Pharmacol. Sci.* **39**, 354–366
 26. Freedman, R., and Goldowitz, D. (2010) Studies on the hippocampal formation: From basic development to clinical applications: Studies on schizophrenia. *Prog. Neurobiol.* **90**, 263–275
 27. Yakel, J. L. (2013) Cholinergic receptors: Functional role of nicotinic ACh receptors in brain circuits and disease. *Pflugers Arch.* **465**, 441–450
 28. Dineley, K. T., Pandya, A. A., and Yakel, J. L. (2015) Nicotinic ACh receptors as therapeutic targets in CNS disorders. *Trends Pharmacol. Sci.* **36**, 96–108
 29. Sadigh-Eteghad, S., Majdi, A., Talebi, M., Mahmoudi, J., and Babri, S. (2015) Regulation of nicotinic acetylcholine receptors in Alzheimer's disease: A possible role of chaperones. *Eur. J. Pharmacol.* **755**, 34–41
 30. Locke, D. P., Archidiacono, N., Misceo, D., Cardone, M. F., Deschamps, S., Roe, B., Rocchi, M., and Eichler, E. E. (2003) Refinement of a chimpanzee pericentric inversion breakpoint to a segmental duplication cluster. *Genome Biol.* **4**, R50
 31. Gault, J., Robinson, M., Berger, R., Drebing, C., Logel, J., Hopkins, J., Moore, T., Jacobs, S., Meriwether, J., Choi, M. J., Kim, E. J., Walton, K., Buiting, K., Davis, A., Breese, C., *et al.* (1998) Genomic organization and partial duplication of the human $\alpha 7$ neuronal nicotinic acetylcholine receptor gene (*CHRNA7*). *Genomics* **52**, 173–185
 32. Riley, B., Williamson, M., Collier, D., Wilkie, H., and Makoff, A. (2002) A 3-Mb map of a large segmental duplication overlapping the $\alpha 7$ -nicotinic acetylcholine receptor gene (*CHRNA7*) at human 15q13-q14. *Genomics* **79**, 197–209
 33. Sinkus, M. L., Lee, M. J., Gault, J., Logel, J., Short, M., Freedman, R., Christian, S. L., Lyon, J., and Leonard, S. (2009) A 2-base pair deletion polymorphism in the partial duplication of the $\alpha 7$ nicotinic acetylcholine gene (*CHRFAM7A*) on chromosome 15q14 is associated with schizophrenia. *Brain Res.* **1291**, 1–11
 34. Kunii, Y., Zhang, W., Xu, Q., Hyde, T. M., McFadden, W., Shin, J. H., Deep-Soboslay, A., Ye, T., Li, C., Kleinman, J. E., Wang, K. H., and Lipska, B. K. (2015) *CHRNA7* and *CHRFAM7A* mRNAs: Co-localized and their expression levels altered in the postmortem dorsolateral prefrontal cortex in major psychiatric disorders. *Am. J. Psychiatry* **172**, 1122–1130
 35. Kalmady, S. V., Agrawal, R., Venugopal, D., Shivakumar, V., Amaresha, A. C., Agarwal, S. M., Subbanna, M., Rajasekaran, A., Narayanaswamy, J. C., Debnath, M., and Venkatasubramanian, G. (2018) *CHRFAM7A* gene expression in schizophrenia: Clinical correlates and the effect of anti-psychotic treatment. *J. Neural Transm. (Vienna)* **125**, 741–748
 36. de Lucas-Cerrillo, A. M., Maldifassi, M. C., Arnalich, F., Renart, J., Atienza, G., Serantes, R., Cruces, J., Sánchez-Pacheco, A., Andrés-Mateos, E., and Montiel, C. (2011) Function of partially duplicated human $\alpha 7$ nicotinic receptor subunit *CHRFAM7A* gene: Potential implications for the cholinergic anti-inflammatory response. *J. Biol. Chem.* **286**, 594–606
 37. Araud, T., Graw, S., Berger, R., Lee, M., Neveu, E., Bertrand, D., and Leonard, S. (2011) The chimeric gene *CHRFAM7A*, a partial duplication of the *CHRNA7* gene, is a dominant negative regulator of $\alpha 7$ nAChR function. *Biochem. Pharmacol.* **82**, 904–914
 38. Cedillo, J. L., Bordas, A., Arnalich, F., Esteban-Rodríguez, I., Martín-Sánchez, C., Extremera, M., Atienza, G., Rios, J. J., Arribas, R. L., and Montiel, C. (2019) Anti-tumoral activity of the human-specific duplicated form of $\alpha 7$ -nicotinic receptor subunit in tobacco-induced lung cancer progression. *Lung Cancer* **128**, 134–144
 39. Maldifassi, M. C., Martín-Sánchez, C., Atienza, G., Cedillo, J. L., Arnalich, F., Bordas, A., Zafra, F., Gimenez, C., Extremera, M., Renart, J., and Montiel, C. (2018) Interaction of the $\alpha 7$ -nicotinic subunit with its human-specific duplicated *dupa7* isoform in mammalian cells: Relevance in human inflammatory responses. *J. Biol. Chem.* **293**, 13874–13888
 40. Costantini, T. W., Dang, X., Coimbra, R., Eliceiri, B. P., and Baird, A. (2015) *CHRFAM7A*, a human-specific and partially duplicated $\alpha 7$ -nicotinic acetylcholine receptor gene with the potential to specify a human-specific inflammatory response to injury. *J. Leukoc. Biol.* **97**, 247–257
 41. Rossi, S., Singer, S., Shearman, E., Sershen, H., and Lajtha, A. (2005) The effects of cholinergic and dopaminergic antagonists on nicotine-induced cerebral neurotransmitter changes. *Neurochem. Res.* **30**, 541–558
 42. Faro, L. R. F., Tak-Kim, H., Alfonso, M., and Duran, R. (2019) Clothianidin, a neonicotinoid insecticide, activates $\alpha 4\beta 2$, $\alpha 7$ and muscarinic receptors to induce *in vivo* dopamine release from rat striatum. *Toxicology* **426**, 152285
 43. Maurisse, R., De Semir, D., Emamekhoo, H., Bedayat, B., Abdolmohammadi, A., Parsi, H., and Gruenert, D. C. (2010) Comparative transfection of DNA into primary and transformed mammalian cells from different lineages. *BMC Biotechnol.* **10**, 9
 44. Hashemi, A., Roohvand, F., Ghahremani, M. H., Aghasadeghi, M. R., Vahabpour, R., Motevau, F., and Memarnejadian, A. (2012) Optimization of transfection methods for Huh-7 and Vero cells: Comparative study. *Tsitol. Genet.* **46**, 19–27
 45. Sharifi Tabar, M., Hesaraki, M., Esfandiari, F., Sahraneshin Samani, F., Vakilian, H., and Baharvand, H. (2015) Evaluating electroporation and lipofectamine approaches for transient and stable transgene expressions in human fibroblasts and embryonic stem cells. *Cell J.* **17**, 438–450
 46. Magin, S., Saha, J., Wang, M., Mladenova, V., Coym, N., and Iliakis, G. (2013) Lipofection and nucleofection of substrate plasmid can generate widely different readings of DNA end-joining efficiency in different cell lines. *DNA Repair (Amst.)* **12**, 148–160
 47. Vogel, C., and Marcotte, E. M. (2012) Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. *Nat. Rev. Genet.* **13**, 227–232
 48. Ly, T., Ahmad, Y., Shlien, A., Soroka, D., Mills, A., Emanuele, M. J., Stratton, M. R., and Lamond, A. I. (2014) A proteomic chronology of gene expression through the cell cycle in human myeloid leukemia cells. *Elife* **3**, e01630
 49. Beilharz, T. H., and Preiss, T. (2004) Translational profiling: The genome-wide measure of the nascent proteome. *Brief Funct. Genomic Proteomic* **3**, 103–111

50. Beyer, A., Hollunder, J., Nasheuer, H., and Wilhelm, T. (2004) Post-transcriptional expression regulation in the yeast *Saccharomyces cerevisiae* on a genomic scale. *Mol. Cell. Proteomics* **3**, 1083–1092
51. Brockmann, R., Beyer, A., Heinisch, J. J., and Wilhelm, T. (2007) Post-transcriptional expression regulation: What determines translation rates? *PLoS Comput. Biol.* **3**, e57
52. Arava, Y., Wang, Y., Storey, J. D., Liu, C. L., Brown, P. O., and Herschlag, D. (2003) Genome-wide analysis of mRNA translation profiles in *Saccharomyces cerevisiae*. *Proc. Natl. Acad. Sci. U. S. A.* **100**, 3889–3894
53. Wang, Y., Xiao, C., Indersmitten, T., Freedman, R., Leonard, S., and Lester, H. A. (2014) The duplicated $\alpha 7$ subunits assemble and form functional nicotinic receptors with the full-length $\alpha 7$. *J. Biol. Chem.* **289**, 26451–26463
54. Lasala, M., Corradi, J., Bruzzone, A., Esandi, M. D. C., and Bouzat, C. (2018) A human-specific, truncated $\alpha 7$ nicotinic receptor subunit assembles with full-length $\alpha 7$ and forms functional receptors with different stoichiometries. *J. Biol. Chem.* **293**, 10707–10717
55. Chan, T., Williams, E., Cohen, O., Eliceiri, B. P., Baird, A., and Costantini, T. W. (2019) *CHRFAM7A* alters binding to the neuronal alpha-7 nicotinic acetylcholine receptor. *Neurosci. Lett.* **690**, 126–131
56. Hajós, M., Hurst, R. S., Hoffmann, W. E., Krause, M., Wall, T. M., Higdon, N. R., and Groppi, V. E. (2005) The selective alpha7 nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetized rats. *J. Pharmacol. Exp. Ther.* **312**, 1213–1222
57. Hurst, R. S., Hajós, M., Raggenbass, M., Wall, T. M., Higdon, N. R., Lawson, J. A., Rutherford-Root, K. L., Berkenpas, M. B., Hoffmann, W. E., Piotrowski, D. W., Groppi, V. E., Allaman, G., Ogier, R., Bertrand, S., Bertrand, D., *et al.* (2005) A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: *In vitro* and *in vivo* characterization. *J. Neurosci.* **25**, 4396–4405
58. Grønlien, J. H., Håkerud, M., Ween, H., Thorin-Hagene, K., Briggs, C. A., Gopalakrishnan, M., and Malysz, J. (2007) Distinct profiles of alpha7 nAChR positive allosteric modulation revealed by structurally diverse chemotypes. *Mol. Pharmacol.* **72**, 715–724
59. Bordas, A., Cedillo, J. L., Arnalich, F., Esteban-Rodriguez, I., Guerra-Pastrián, L., de Castro, J., Martín-Sánchez, C., Atienza, G., Fernández-Capitan, C., Rios, J. J., and Montiel, C. (2017) Expression patterns for nicotinic acetylcholine receptor subunit genes in smoking-related lung cancers. *Oncotarget* **8**, 67878–67890
60. Cedillo, J. L., Arnalich, F., Martín-Sánchez, C., Quesada, A., Rios, J. J., Maldifassi, M. C., Atienza, G., Renart, J., Fernández-Capitán, C., García-Rio, F., López-Collazo, E., and Montiel, C. (2015) Usefulness of $\alpha 7$ nicotinic receptor messenger RNA levels in peripheral blood mononuclear cells as a marker for cholinergic antiinflammatory pathway activity in septic patients: Results of a pilot study. *J. Infect. Dis.* **211**, 146–155
61. Maldifassi, M. C., Atienza, G., Arnalich, F., López-Collazo, E., Cedillo, J. L., Martín-Sánchez, C., Bordas, A., Renart, J., and Montiel, C. (2014) A new IRAK-M-mediated mechanism implicated in the anti-inflammatory effect of nicotine via $\alpha 7$ nicotinic receptors in human macrophages. *PLoS One* **9**, e108397